Zimmer Biomet

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Zimmer Biomet and other ETFs, options, and stocks.

About ZBH

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. 

CEO
Ivan Tornos
CEOIvan Tornos
Employees
17,000
Employees17,000
Headquarters
Warsaw, Indiana
HeadquartersWarsaw, Indiana
Founded
1927
Founded1927
Employees
17,000
Employees17,000

ZBH Key Statistics

Market cap
16.45B
Market cap16.45B
Price-Earnings ratio
23.69
Price-Earnings ratio23.69
Dividend yield
1.05%
Dividend yield1.05%
Average volume
2.29M
Average volume2.29M
High today
$91.14
High today$91.14
Low today
$84.05
Low today$84.05
Open price
$89.05
Open price$89.05
Volume
1.43M
Volume1.43M
52 Week high
$108.29
52 Week high$108.29
52 Week low
$79.12
52 Week low$79.12

Stock Snapshot

As of today, Zimmer Biomet(ZBH) shares are valued at $85.01. The company's market cap stands at 16.45B, with a P/E ratio of 23.69 and a dividend yield of 1.05%.

As of 2026-06-30, Zimmer Biomet(ZBH) stock has fluctuated between $84.05 and $91.14. The current price stands at $85.01, placing the stock +1.1% above today's low and -6.7% off the high.

The Zimmer Biomet(ZBH)'s current trading volume is 1.43M, compared to an average daily volume of 2.29M.

In the last year, Zimmer Biomet(ZBH) shares hit a 52-week high of $108.29 and a 52-week low of $79.12.

In the last year, Zimmer Biomet(ZBH) shares hit a 52-week high of $108.29 and a 52-week low of $79.12.

ZBH News

Nasdaq 3h
Pacira To Sell Iovera Business To Zimmer Biomet; Pacira Shares Up

(RTTNews) - Pacira BioSciences Inc. (PCRX) on Tuesday announced an agreement to divest its iovera business to Zimmer Biomet Holdings (ZBH) for up to $140 millio...

Pacira To Sell Iovera Business To Zimmer Biomet; Pacira Shares Up
TipRanks 4h
Pacira Zimmer to divest iovera degrees to Biomet for $70M upfront

Pacira (PCRX) announced the divestiture of iovera degrees to Zimmer Biomet (ZBH). The iovera degrees system is a FDA-cleared, drug-free medical device that reli...

MarketWatch 18h
Zimmer Biomet Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch

...

Zimmer Biomet Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch

Analyst ratings

66%

of 29 ratings
Buy
31%
Hold
65.5%
Sell
3.4%

More ZBH News

Simply Wall St 3d
Zimmer Biomet Raises EPS Outlook on Robotics Gains Is Its Transformation Story Taking Shape?

Earlier this week, Zimmer Biomet Holdings reaffirmed its 1–3% revenue growth guidance and raised its earnings-per-share outlook, citing early benefits from its...

Zimmer Biomet Raises EPS Outlook on Robotics Gains Is Its Transformation Story Taking Shape?
Simply Wall St 4d
Is Zimmer Biomet Holdings Undervalued After Raising Earnings Guidance?

Zimmer Biomet Holdings (ZBH) recently reaffirmed its 1% to 3% revenue growth outlook while lifting earnings guidance, highlighting early benefits from its comme...

Is Zimmer Biomet Holdings Undervalued After Raising Earnings Guidance?

People also own

Based on the portfolios of people who own ZBH. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.